Melanoma-associated antigen 3 peptide presented by Human Leukocyte Antigen A2 (MAGEA3-HLA-A2)

Melanoma-associated antigen 3 (MAGEA3) peptide presented by Human Leukocyte Antigen A2 (HLA-A2) is a peptide-major histocompatibility complex (pMHC) that serves as a highly specific target for cancer immunotherapy. MAGEA3 is a member of the cancer-testis antigen family, which is typically expressed only in male germ cells and various malignancies, making it an ideal target for minimizing off-tumor effects in most adult tissues. The HLA-A2 allele, particularly the HLA-A*02:01 subtype, is one of the most prevalent MHC Class I molecules and presents specific MAGEA3-derived peptides, such as FLWGPRALV and KVAELVHFL, to CD8+ cytotoxic T lymphocytes. Therapeutic strategies targeting this complex include T-cell receptor (TCR)-engineered T-cell therapies and cancer vaccines, which aim to induce a robust anti-tumor immune response. However, clinical development has faced significant challenges, including lethal off-target toxicities. For instance, affinity-enhanced TCRs targeting this complex have shown severe neurotoxicity in clinical trials due to cross-reactivity with MAGE-A12 expressed in the central nervous system. Despite these safety concerns, the MAGEA3-HLA-A2 complex remains a prominent target for developing next-generation immunotherapies with refined specificity.

Other names

MAGE-A3/HLA-A2 complexMAGE-A3:112-120/HLA-A*02:01MAGE-A3:271-279/HLA-A*02:01HLA-A2-restricted MAGE-A3 epitopeMAGE-A3 pMHCMAGEA3-HLA-A*02:01

T-cell receptor (TCR) binding to the peptide-MHC complex, leading to T-cell activation and cytotoxic killing of tumor cells.